“4 Stocks to Buy Before the End of 2026!”
$BLLNBullish
AI summary · BillionToOne is a buy: its QCT platform's single-molecule counting gives sensitivity traditional diagnostics generally cannot match, and oncology liquid biopsy, which the speaker expects to matter most to growth, grew 96% year over year to about a $68 million annual rate. Revenue beat consensus by about 50%, EPS more than doubled estimates, prenatal revenue rose 41%, and a fifth straight quarter of positive GAAP operating income came with about $9 million free cash flow and $562 million cash; a mid-December minimal residual disease test launch is key to that oncology build-out.
For the last stock in today's video, I'll be talking about another name in the healthcare sector, another name that is perhaps a little less well known. I'm trying to change things up a bit.
We sometimes see in the comments that you mention we're only talking about technology stocks, so I'm trying to change the atmosphere a little. We'll see. So, BillionToOne, its symbol is BLLN.
What they said to watch for